Compare ROAD & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROAD | SYRE |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.5B |
| IPO Year | 2018 | 2015 |
| Metric | ROAD | SYRE |
|---|---|---|
| Price | $102.85 | $88.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $127.80 | $85.08 |
| AVG Volume (30 Days) | 658.2K | ★ 1.7M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.46 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $785,679,000.00 | N/A |
| Revenue This Year | $27.79 | N/A |
| Revenue Next Year | $10.29 | N/A |
| P/E Ratio | $229.77 | ★ N/A |
| Revenue Growth | ★ 0.31 | N/A |
| 52 Week Low | $93.22 | $14.51 |
| 52 Week High | $151.00 | $102.06 |
| Indicator | ROAD | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 34.22 | 57.28 |
| Support Level | $95.01 | $66.78 |
| Resistance Level | $117.31 | $102.06 |
| Average True Range (ATR) | 6.00 | 4.86 |
| MACD | -1.87 | -0.58 |
| Stochastic Oscillator | 1.25 | 36.87 |
Construction Partners Inc operates as a civil infrastructure company. It specializes in the construction and maintenance of roadways. The company through its subsidiaries, provides various products and services to both public and private infrastructure projects, with an emphasis on highways, roads, bridges, airports, and commercial and residential developments. Its operations consist of manufacturing and distributing hot mix asphalt, paving activities, including the construction of roadway base layers and application of asphalt pavement, site development, including the installation of utility and drainage systems, and others. The company has a single segment which predominantly consists of infrastructure and road construction, and operates across various states in the United States.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.